When Will Ozempic Be Generic? The Dates, Country by Country

I get asked when will Ozempic be generic about as often as people learn that I write about drug patents, which is to say rarely, but with real feeling. The plain answer is that it already is, in some countries, and will not be for years in others. Generic semaglutide (the molecule inside Ozempic) went on sale in India on March 21, 2026, and Health Canada approved its first generic version on April 28, 2026. In the United States, the core compound patent runs to December 5, 2031, and Novo Nordisk itself reports 2032 as the effective expiry.

So the answer depends on where you live. The EU and UK are protected until about March 2031, and Japan until around 2031. China’s patent expired in March 2026, but a separate data protection rule keeps generics out until about April 2027. The research site Generic Guide put it this way as of September 2026: “generic semaglutide is on sale in India, Canada, Brazil, South Africa, and Saudi Arabia, but China and Mexico remain closed by data protection.” Same molecule. Different calendars.

Start with one patent, then make it worse

Here is the reasonable version. You invent a useful molecule. The government says that for a set number of years nobody else can make it, and in exchange you publish how it works. When the time runs out, anyone can copy it and the price falls. That’s fine. It is a sensible bargain, and most people nod when they hear it.

Now add one step. A drug takes years to get approved, and the patent clock runs that whole time while you sell nothing. So the government gives some of the time back. In plain words: you get to be the only seller for a while, and then, because the government was slow to let you start selling, you get to be the only seller a bit longer to make up for it. This is called patent term restoration, and it is why the US compound patent on semaglutide, US 8,129,343, runs to December 5, 2031.

Another step. Patents are national. Each country grants its own, on its own schedule, with its own extensions (Europe calls its version a supplementary protection certificate, which is a very European name for a coupon). So one molecule can be expired in one country and protected next door. Messier, but still defensible.

Another step. Even after the patent ends, a regulator may refuse, for some years, to let a copycat lean on the original company’s clinical trial data. That is data protection, a second lock on the same door. So a patent can die and nothing happens.

Another step. Patents cost money to keep alive. Many countries charge periodic maintenance fees, and if you skip one, the patent lapses for good. So the monopoly on one of the most valuable drugs in the world could, in principle, end over an unpaid bill.

The absurd endpoint: the answer to “when can anyone sell a cheap copy of this drug” becomes a function of your country, that country’s data rules, the shape of the injection pen, and whether a small payment went out in 2019. We are there. Every step.

India: the patent ended and the generics arrived the next day

Novo Nordisk’s compound patent on semaglutide lapsed in India on March 20, 2026. Generic launches began March 21. More than 40 brands went on sale, with more than a dozen manufacturers launching on day one. Generic makers had been flirting with this market for a while (Sun Pharmaceutical, Zydus Lifesciences and Alkem Laboratories got Indian approval to manufacture and sell generic versions back in January 2026), and the relationship went public at the first legal opportunity. I like to imagine someone at a generic company saying “okay, everyone, tomorrow” on March 20 and meaning it literally, though I have no record of anyone saying that.

The prices did what the textbook says. Ozempic had cost about ₹8,800 to ₹11,175 a month (roughly $105 to $135), and Wegovy up to ₹16,400. Generics came in at ₹1,800 to ₹4,200 a month (roughly $20 to $50). About ten days later, Novo Nordisk cut its Ozempic price in India by 36% and its Wegovy price by 48%. By April, generics had taken 50% of India’s semaglutide sales by value.

People noticed, presumably.

There is a catch, because there is always a catch. A formulation patent covering the absorption enhancer in the oral tablet runs to 2031 in India. So the injectable is generic and the pill is not. Same molecule, different stuff around it.

Canada: the patent that ended over a fee

Canada is the step-five country. Novo Nordisk did not pay a 250 Canadian dollar maintenance fee (roughly $180) in 2019, and its patent, CA 2601784, lapsed permanently. Data protection ended January 4, 2026. Health Canada approved Dr. Reddy’s Laboratories’ generic semaglutide injection on April 28, 2026, and the agency’s own description is that Canada was “the first G7 country to approve a generic version of semaglutide.” Apotex got a second approval on May 1, 2026, a generic Ozempic for adults with type 2 diabetes, under the press-release headline “Apotex Becomes the First Canadian-Based Pharmaceutical Company to Receive Health Canada Approval for a Generic Equivalent of Ozempic.” Generic launches began from mid-May.

For scale: Ozempic was Canada’s best-selling drug in 2025, with $2.9 billion in sales, more than three times the next drug on the list, and over a million Canadians were taking it when the generic was approved. A fairly popular product.

You and I are both picturing the 2019 accounts-payable meeting. The facts say nothing about it, and why the fee went unpaid is not settled. It is the reverse of the gym membership you forgot to cancel: someone forgot to keep paying, and the membership actually ended.

It is not a clean sweep, though. Pen device patents in Canada are reported to run to at least 2033, and Wegovy, the higher-dose obesity version, was reported as still patent-protected when Apotex’s approval came through. Patents are layered like that.

China: the patent expired and nothing happened

China is the step-four country. The same compound patent expired there on March 20, 2026, the same day as India. But China’s data exclusivity runs to about April 2027, and as of October 2026, zero generic semaglutide products had been approved in mainland China. The patent is gone. The door is still locked.

The generic makers are presumably standing outside it anyway. Dr. Reddy’s announced in July 2025 that it planned to launch generic Wegovy in 87 countries in 2026, beginning with Canada, India, Brazil and Turkey. China is a different calendar.

When will Ozempic be generic in the US? 2031, or 2032, or later

The United States is every step at once. The compound patent is extended by restoration to December 5, 2031. Novo Nordisk said in its 2025 annual filing that the effective US compound expiry for Ozempic, Rybelsus and Wegovy is 2032. DrugPatentWatch also says 2032, which conflicts with the December 2031 date. Which one governs in practice is not settled by these facts, and the gap is about a month, so it may not matter much (or it may matter a lot to whoever wants to launch on day one).

Then come the secondary patents. US patents tied to Ozempic run to 2031, 2034 and 2037, covering oral dosing, solid compositions with absorption enhancers and the injection pen, with secondary protection reaching as far as 2038. Rybelsus, the pill, has an estimated US generic launch date of May 2, 2034. Whether a generic injection can launch in 2032 without tripping over a pen patent is the kind of thing lawyers get paid to argue about, and the facts here do not say how that argument ends.

Meanwhile the generic is, in some sense, already approved. On April 10, 2026, Apotex received the first US FDA tentative approval for a generic Ozempic. Tentative approval means the FDA has reviewed the product and is satisfied with it, but it cannot be sold until the patents allow. It is the regulator saying “this looks great, please wait five years,” lol.

I mean, the system is working as designed. Each step was reasonable when someone added it. Stack them up, though, and a type 2 diabetes patient in Toronto and one in Toledo are on opposite sides of a 2019 invoice, a December 2031 extension and a pen.

A patent is a fact about a place, not about a molecule.